Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

July 10, 2007 at 5:40 PM

Northwest Biotherapeutics gets Swiss jolt

It seems Northwest Biotherapeutics, a local biotech once derided by U.S. capital markets, is benefitting from the Alpine climate.

Shortly after its debut at London Stock Exchange’s stock market for small caps, the company said that Swiss regulatory authorities approved the use of its brain cancer therapeutic vaccine.

The announcement, sent the stock into a wild ride Monday, closing 36 percent higher in London’s Alternative Investment Market. The stock jumped even higher on Tuesday — to an unbelievable 280 pence, up 104 percent.

Not bad for a Bothell-based company that was once kicked out of Nasdaq for running out of cash.

Chief Executive Alton Boynton said:

“Switzerland is an attractive place to begin commercialization, due to its highly respected regulatory oversight, and its growing experience with cellular therapies. Switzerland is also increasingly noted for medical tourism, and is easily accessible for many medical tourists.”

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►